Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Parestat is a generic injectable formulation of parecoxib sodium, which serves as a selective cyclooxygenase-2 (COX-2) inhibitor and a prodrug of valdecoxib. It is primarily utilized for the short-term management of acute postoperative pain. Upon administration, Parestat is rapidly converted by enzymatic hydrolysis into valdecoxib, which then inhibits the COX-2 enzyme, blocking the synthesis of prostaglandins that mediate pain, fever, and inflammation. Because it selectively targets COX-2 over COX-1 at therapeutic concentrations, it provides effective analgesia with a reduced risk of the gastrointestinal and platelet-related side effects commonly associated with non-selective nonsteroidal anti-inflammatory drugs (NSAIDs). It is typically administered via intravenous or intramuscular injection in a hospital setting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Parestat.